A Phase 1 Study of HRO761 for People With Advanced Solid Tumors


Full Title

An Open-label, Multi-Center Phase I/Ib Dose Finding and Expansion Study of HRO761 as Single Agent and in Combinations in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors


Researchers want to find the highest dose of HRO761 to use in people with advanced solid tumors. The people in this study have solid tumors that have metastasized (spread). In addition, their cancers are mismatch repair deficient (dMMR) or microsatellite unstable (MSI-high). This means their cancer cells are less able to correct mistakes in their DNA.

HRO761 blocks a protein called WRN, which may fuel cancer growth. By blocking this protein, HRO761 may slow or stop the growth of cancer cells while sparing healthy cells. HRO761 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a metastatic solid tumor that is dMMR or MSI-high and keeps growing even with treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Michael Foote’s office at 646-888-5261.




Phase I (phase 1)

Disease Status

Newly Diagnosed & Relapsed/Refractory




ClinicalTrials.gov ID